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AN important question about FK 506 concerns the 
nature and extent of any side effects associated with 
its clinical use. Because the issues of renal and metabolic 
effects are addressed in other papers, the discussion here 
will focus on patient symptoms associated with intrave-
nous and oral FK 506. Since the experience in primarily 
treated and rescue patients has been so different, the two 
groups will be described separately. Most of the side 
effects are associated with intravenous FK 506; taken 
orally, the drug is associated with few or no symptoms. 
PRIMARY FK 506 GROUP 
Of 31 patients undergoing liver transplantation and treated 
primarily with FK 506 and low-dose steroids, 42% had no 
reported or observable side effects associated with intra-
venous FK 506, and 87% had no symptoms with oral FK 
506 (Table I). The most common side effects noted with 
intravenous FK 506 were mild nausea and headache; each 
symptom was seen in 32% of the patients. No patient in the 
primary group required antiemetic or analgesic therapy. A 
curious sensation of warmth or hyperesthesia, either sys-
temic or localized to the extremities, was noted in 23% of 
patients receiving intravenous FK 506; this effect was not 
seen with the oral form of the drug. A possible variation of 
this symptom was circumoral numbness and tingling asso-
ciated with each intravenous dose; this was seen in three 
patients (10%), and disappeared with conversion to oral 
FK 506. 
Unusual side effects included tremors, seen in two 
Table 1. Side Effects In 31 Patients Treated Primarily With 
FK506 
Side Etlects IV(%) PO(%) 
Headache 32 6 
Nausea 32 0 
Sensetion of warmth! 
hyperesthesia 23 0 
Circumoral numb-
ness, tingling 10 0 
Tremors 6 3 
Abdominal pain 3 0 
Chest pain 3 0 
Flushing 3 0 
Itching 3 0 
Vomiting 3 0 
Insomnia 0 10 
Sensation of racing 0 6 
Hair loss 0 3 
Increasad hair 
growth 0 3 
No symptoms 42 87 
patients (6%). Itching, flushing, abdominal pain (without 
clinical sequelae), vomiting. and chest pain (without elec-
trocardiographic changes) were each seen in one patient 
(3%). Generally, most symptoms began about 30 minutes 
after the beginning of the intravenous dose and lasted for 
about 1 hour after the completion of the infusion. 
Only four patients (13%) had any symptoms associated 
with oral FK 506. Three patients (10%) complained of 
insomnia, and this problem disappeared when the dose of 
FK 506 was reduced. Two patients (6%) noted headache, 
and two patients had a sensation of "racing." Tremors, 
hair loss, and excessive hair growth were each seen in one 
patient (3%). In general. the few symptoms associated with 
oral FK 506 were of minor significance and tended to 
disappear following dose reduction. 
RESCUE FK 506 GROUP 
Thirty-one patients receiving FK 506 as rescue therapy 
after liver or kidney transplantation were studied. The 
rescue protocol called for both intravenous CyA and FK 
506 to be administered on successive days. The greatest 
number and· the only significant side effects were seen 
during this conversion to intravenous FK 506 (Table 2), 
when patients had therapeutic blood levels ofCyA. Every 
patient in the rescue group had one or more symptoms 
associated with intravenous FK 506. Seventy-seven per-
cent had headaches of varying severity; during the period 
of the trial in which combined intravenous Cy A and FK 
506 were given, most patients needed no analgesic ther-
apy. while the first few patients actually required narcot-
ics. Nausea was also a common side effect and was seen in 
65% of patients; again. antiemetics were only required in 
the first few patients who had received high doses of 
intravenous CyA and FK 506. Vomiting or diarrhea were 
less common and were seen in 35% of patients. 
The sensation of warmth or hyperesthesia was seen in 
61% of the patients receiving intravenous FK 506 as rescue 
therapy. Less common side effects were flushing or itch-
ing, seen in 16% of the patients, and tremors, noted in 13% 
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Table 2. Side Eftecta In 31 Patients Trellted with FK 506 aa 
Rescue Therepy 
Side Effects IV(%) PO(%) 
Headache n 6 
Nausea 65 10 
Sensation of warmth! 
hyperesthesia 61 0 
Diarrhea 35 6 
Vomiting 35 10 
Flushing 16 0 
Itching 16 0 
Tremors 13 0 
Anxiety 10 0 
Chest pain 10 0 
Rash 10 0 
Anorexia 6 6 
Shortness of breath 6 0 
Abdominal cramping 3 0 
Abdominal pain 3 0 
Blurred vision 3 0 
Fatigue 3 0 
Night sweats 3 0 
Photophobia 3 0 
Hair loss 0 6 
No symptoms 0 74 
of patients. There were a number of side effects noted less 
frequently. These included rash (10%), chest pain (10%; 
without electrocardiographic changes or creatine phos-
phokinase-MB enzyme elevations), acute anxiety (10%), 
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anorexia (6%), shortness of breath (6%; without clinical 
sequelae), abdominal pain or cramping (6%), night sweats 
(3%), fatigue (3%), photophobia (3%), and blurred vision 
(3%). 
After conversion to oral FK 506 and elimination of Cy A, 
the range and frequency of side effects declined markedly. 
Nausea and vomiting were seen episodically in 10% of 
patients; headaches, diarrhea, anorexia, and a question of 
hair loss were each seen in 6%. These side effects were 
sporadic and disappeared within a few weeks. Seventy-
four percent of the rescue patients had no side effects after 
conversion to oral FK 506. 
DISCUSSION 
FK 506 has relatively few side effects in primarily treated 
patients. The symptoms thus far have been minor and have 
been seen for the most part only after intravenous admin-
istration of the drug. The most common side effects were 
headache, nausea, vomiting, and flushing. A significantly 
higher incidence of these side effects was noted in the 
rescue group receiving intravenous FK 506, and this, plus 
the other adverse interactions described elsewhere in this 
symposium, makes us recommend for fresh cases that FK 
506 and Cy A not be used together. 
